People with haemophilia now have subsidised access to two Extended Half-Life (EHL) replacement treatments that will reduce their need for frequent infusions. From 1 July, efmoroctocog alfa (Eloctate and Adynovate) and eftrenonacog alfa (Alprolix) will be reimbursed for people with haemophilia A and B respectively, by the National Blood Authority. “This means that there is ...
Extended half life clotting factor products now reimbursed for haemophilia A and B
By Michael Woodhead
8 Jul 2020